CDK4 and head and neck squamous cell carcinoma: Thus, the examination of palbociclib-based drug combinations provides insights into the systematic combinatory effects associated with CDK4/6 inhibition and supports further exploration of biomarker-guided clinical trials using palbociclib plus alpelisib combination in HPVneg HNSCC.